26
Mar
2020
Adjusting to Telemedicine: A First-Hand Account
One consequence of the present crisis is the urgent embrace of telemedicine, as I recently discussed. Whether the adoption is sustained beyond the crisis period remains to be determined, although use seemed to be increasing overall even before the pandemic hit. As more physicians and patients find themselves pressed to adopt telemedicine, I thought it might be helpful to better... Read More
26
Mar
2020
The Coronavirus Tsunami, Lyell’s $492M Megaround & Some Deals You Missed
When a story moves with exponential speed and deadly force, it’s hard for a human being to keep up. Hard for you, and hard for me. My approach these past few weeks has been to work with purpose and passion on this story that touches all of humanity. The plan has been to seek out diverse voices with fresh perspectives... Read More
26
Mar
2020
Pharmacy as the Biomarker of Biopharma’s Strategic Change, After Coronavirus
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Mar
2020
We Interrupt This Nightmare to Bring You a Few Giggles
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Mar
2020
Unsung Heroes Who Give Me Hope
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Mar
2020
A Surge of Gratitude, From a Doctor on the Front Lines of COVID-19 in Boston
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Mar
2020
What Not To Do: Lessons From Spain’s Cavalier Response to COVID-19
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
24
Mar
2020
Doctor, Mother, CEO: Balancing Competing Needs, and Opting for the Front Lines
Yesterday I woke up on an island. I am temporarily – but purposefully — isolating myself and my two children, ages 10 and 12, in a familiar place that carries with it a slower rhythm from a different time. It’s our second home. It also happens that, on the first day of spring, there are still no cases of suspected... Read More
24
Mar
2020
Digital Tools in Clinical Trials Find Opportunity During Pandemic
The current crisis represents a potentially defining moment for at least some health technologies and technology-enabled services. Telehealth, as discussed in my last column, is one conspicuous example, and the jury is still out. The potential benefit seems especially striking at a time when so many Americans are being told to stay at home, yet there are also serious concerns,... Read More
23
Mar
2020
New Drugs at Low Prices: Alexis Borisy and Melanie Nallicheri of EQRx on The Long Run
Today’s guests on The Long Run are Alexis Borisy and Melanie Nallicheri. Alexis is the chairman and CEO of EQRx, and Melanie is the president and chief operating officer. EQRx is a startup in Cambridge, Massachusetts. It aspires to develop new medicines for serious diseases like cancer. That’s nothing unusual. What is unusual is that EQRx is seeking to create... Read More
23
Mar
2020
Let it Rip or Shelter at Home? Choosing Between Two Bad Options on Coronavirus
Like most of you, I have been obsessively following “the virus.” It is having a devastating impact on human life, hospital systems, governments and economies. The worst is still to come, based on what we know about this new coronavirus and its ability to spread with exponential force. Here are some thoughts on the difficult choices laying ahead. Before I... Read More
23
Mar
2020
Staying Mentally Healthy to Weather the COVID19 Crisis
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Mar
2020
Why Telehealth Champions Are Worried About Trust
Crises can serve as catalysts. History has shown they increase the recognition that change is needed, and lower the activation energy required for it to occur. The COVID-19 crisis has already been widely recognized as potential catalyst for telemedicine, and more generally for the accelerated adoption of digital tools in both clinical medicine and clinical trials. In just the last... Read More
21
Mar
2020
Love in the Time of Coronavirus
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Mar
2020
In Times of Coronavirus Pandemic, it Takes a Global Village
For some US biotech companies today, the ability to maintain business and societal continuity during the COVID–19 pandemic comes with assistance from a surprising source. Contract research organizations (CROs) based in China were the first – and most severely — impacted by the new coronavirus outbreak in January. But they are now rebounding to provide their traditional services to biopharma... Read More
20
Mar
2020
Biotech Can Help the Most Vulnerable. Here’s Are a Few Ways
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Mar
2020
COVID-19 Response – the Roadmap Not Followed
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
19
Mar
2020
Singapore: What We Can Learn From a High-Risk Country’s Response to COVID19
I was born in Malaysia, but left my family for the promised land of Singapore at the age of 12 under a scholarship program known as the ASEAN program. I lived more than half my life in that country, and have long since become a Singaporean. I currently manage a major Singaporean life sciences VC fund from a San Francisco... Read More
19
Mar
2020
The Biopharmaceutical Counterattack
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Mar
2020
8 Days Later: Italy vs. US
The following is an update to my article on March 10, also published on Timmerman Report. The initial article is available (free to read here). Before I begin, I would like to sincerely thank everybody who has reached out with comments / feedback after my first article. Thank you also for the outpouring of well wishes for my family in... Read More